Evidence map›Paper›PMID 26255186›Full record

ArticleClinical rheumatology2015

Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis.

José Félix Restrepo, Inmaculada del Rincón, Daniel F Battafarano, Roy W Haas, Merced Doria, Agustín Escalante

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 7 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 7 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Review
  12. The prevalence of interstitial lung disease and bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Genomic and Serological Rheumatoid Arthritis Biomarkers,Annals of the American Thoracic Society · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

José Félix RestrepoDivision of Rheumatology, Department of Medicine, University of Texas, Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229-3900, USA, restreposuar@uthscsa.edu.
Inmaculada del Rincón
Daniel F Battafarano
Roy W Haas
Merced Doria
Agustín Escalante
The University of Texas Health Science Center at San Antonio · USSan Antonio Military Medical Center · US

Funding

INSTITUTE FOR INTEGRATION OF MEDICINE & SCIENCE: A PARTNERSHIP TO IMPROVE HEALTHUL1RR025767 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A · 2008 to 2011
$23.8M
The Disablement Process in Rheumatoid ArthritisR01HD037151 · NICHD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ESCALANTE, AGUSTIN · 1999 to 2011
$4.1M
Effect of Chronic Inflammation on Atherosclerosis Outcomes in RAR01HL085742 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DEL RINCON, INMACULADA · 2008 to 2013
$3.6M
Atheroclerosis in rheumatoid arthritis cohortK23HL004481 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DEL RINCON, INMACULADA · 2001 to 2005
$650k
NCRR NIH HHS UL1-RR-025767NHLBI NIH HHS K23-HL-004481NHLBI NIH HHS R01-HL-085742NICHD NIH HHS R01-HD-037151
6 · The paper itself

Abstract

objectiveThe objective of this study is to examine the clinical, genetic, and environmental factors associated with interstitial lung disease (ILD) in rheumatoid arthritis (RA).

methodWe recruited patients with RA from rheumatology practices at the time of a scheduled visit. Each patient participated in a comprehensive assessment that included ascertainment of age, sex, joint tenderness and swelling, subcutaneous nodules, disease severity, use of methotrexate and prednisone, smoking status, rheumatoid factor (RF), antibodies against cyclic citrullinated peptide (anti-CCP),erythrocyte sedimentation rate (ESR), the 28-joint Disease Activity Score (DAS28), and the presence of the HLA-DRB1 shared epitope (SE). As part of a thorough quantification of comorbidity, we identify all comorbid conditions, including ILD. We examined variables associated with ILD using logistic regression. We tested interaction terms between SE and other covariates.

resultsWe studied 779 RA patients, among whom, ILD was recognized clinically in 69 (8.8 %). Variables significantly associated with ILD in a multivariable analysis included male sex, RA duration, the ESR, the DAS28, anti-CCP, and RF. There was a significant interaction between the HLA-DRB1 SE and smoking, ILD being associated with smoking only in the presence of SE. The association between ILD and anti-CCP, RF, and the ESR displayed a biological gradient, higher titers being more strongly associated with ILD.

conclusionAnti-CCP antibodies and the RF may be pathogenically related to ILD. The association between ILD and smoking is dependent on the HLA-DRB1 SE, which may reflect gene-environment interaction.

Indexed as

AdultAgedAllelesArthritis, RheumatoidBlood SedimentationDisease ProgressionFemaleGenetic Predisposition to DiseaseHLA-DRB1 ChainsHumansLogistic ModelsLung Diseases, InterstitialMaleMethotrexateMiddle AgedPeptides, Cycliccyclic citrullinated peptideHLA-DRB1 ChainsMethotrexatePeptides, CyclicRheumatoid Factor

Identifiers

PMID26255186
OpenAlexW1844350523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.